By identifying drugs that restore mitochondrial function to a non-diseased state, Path Therapeutics is able to identify drugs with unexpected mechanisms of action. Path Therapeutics' drug screening platform is based on the knowledge that restoration of neurometabolic outputs to baseline levels can improve the symptoms of many brain disorders, including seizures. Path is currently optimizing its lead compound, PT-320, which restores cellular bioenergetics and decreases seizure frequency in in vivo zebrafish and mouse models of Dravet Syndrome.